ClinicalTrials.gg
CompletedNCT04530838Updated Apr 21, 2023Results posted

20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Healthy Japanese Infants

A Phase 3 interventional study of 20-valent pneumococcal conjugate vaccine and 13-valent pneumococcal conjugate vaccine in Pneumococcal Disease, sponsored by Pfizer. Completed at 38 sites in Japan. Open to participants aged 2 Months to 6 Months, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-04-21.

Sponsored by Pfizer · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
668
Allocation
Randomized
Ages
2 Months to 6 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections — 2 open to participants now, 3 under way, 1 of them phase 3. Pneumococcal 20-Valent Conjugate Vaccine · Pneumococcal Infections.

Enrollment
10th of 19
668 · median 668
Started
2020
with 4 others
Phase 3
14 of 19
1 open now
Registered
7th of 19
by date
Lead sponsor
16 of 19
Pfizer

Among the 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections, this one is the 10th largest by enrollment, is one of 5 that started in 2020, is one of 14 in phase 3, and was the 7th registered.

Pneumococcal Infections

299 studies on the registry are indexed under Pneumococcal Infections; 26 are open to participants now.

Browse Pneumococcal Infections studies →

Open to participants now

2 of the 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About Pneumococcal 20-Valent Conjugate Vaccine

Pneumococcal 20-Valent Conjugate Vaccine: first FDA approval 2021 (Prevnar 20). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.

This study: 2 Months to 6 Months · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections, or all of them as a file.
02

Study summary

20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Healthy Japanese Infants

03

Conditions studied

  • Pneumococcal Disease
04

Who can participate

Ages eligible
2 Months to 6 Months
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Japanese male or female infants ≥2 months to ≤6 months at the time of consent.
  • Healthy infants determined by clinical assessment, including medical history and clinical judgment, to be eligible for the study.

Exclusion criteria

Exclusion Criteria:

  • History of severe adverse reaction associated with a vaccine and/or severe allergic reaction (eg, anaphylaxis)
  • Major known congenital malformation or serious chronic disorder.
  • History of microbiologically proven invasive disease caused by S pneumoniae.
  • Other acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the participant inappropriate for entry into this study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
668 participants (actual)

Study arms

  • Experimental
    20-valent pneumococcal conjugate vaccine (subcutaneous)

    20-valent pneumococcal conjugate vaccine administered by subcutaneous injection (SC)

    Biological: 20-valent pneumococcal conjugate vaccine

  • Active comparator
    13-valent pneumococcal conjugate vaccine (subcutaneous)

    13-valent pneumococcal conjugate vaccine administered by subcutaneous injection (SC)

    Biological: 13-valent pneumococcal conjugate vaccine

  • Experimental
    20-valent pneumococcal conjugate vaccine (intramuscular)

    20-valent pneumococcal conjugate vaccine administered by intramuscular injection (IM)

    Biological: 20-valent pneumococcal conjugate vaccine

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Local Reactions (LR) Within 7 Days After Dose 1

    Local reactions included pain at injection site, redness and swelling were measured and recorded in measuring device (caliper) units. 1 measuring device unit =0.5 centimeter (cm). Pain at injection site was graded as mild: hurts if gently touched; moderate: hurts if gently touched with crying; severe: limited limb movement. Redness and swelling were graded as mild: \>0 to 2.0 cm; moderate \>2.0 to 7.0 cm; and severe: \>7.0 cm.

    Time frame: Within 7 Days after Dose 1

  2. Percentage of Participants With Local Reactions Within 7 Days After Dose 2

    Local reactions included pain at injection site, redness and swelling were measured and recorded in measuring device (caliper) units. 1 measuring device unit =0.5 cm. Pain at injection site was graded as mild: hurts if gently touched; moderate: hurts if gently touched with crying; severe: limited limb movement. Redness and swelling were graded as mild: \>0 to 2.0 cm; moderate \>2.0 to 7.0 cm; and severe: \>7.0 cm.

    Time frame: Within 7 Days after Dose 2

  3. Percentage of Participants With Local Reactions Within 7 Days After Dose 3

    Local reactions included pain at injection site, redness and swelling were measured and recorded in measuring device (caliper) units. 1 measuring device unit =0.5 cm. Pain at injection site was graded as mild: hurts if gently touched; moderate: hurts if gently touched with crying; severe: limited limb movement. Redness and swelling were graded as mild: \>0 to 2.0 cm; moderate \>2.0 to 7.0 cm; and severe: \>7.0 cm.

    Time frame: Within 7 Days after Dose 3

  4. Percentage of Participants With Local Reactions Within 7 Days After Dose 4

    Local reactions included pain at injection site, redness and swelling were measured and recorded in measuring device (caliper) units. 1 measuring device unit =0.5 cm. Pain at injection site was graded as mild: hurts if gently touched; moderate: hurts if gently touched with crying; severe: limited limb movement. Redness and swelling were graded as mild: \>0 to 2.0 cm; moderate \>2.0 to 7.0 cm; and severe: \>7.0 cm.

    Time frame: Within 7 Days after Dose 4

  5. Percentage of Participants With Systemic Events Within 7 Days After Dose 1

    Systemic events included fever, decreased appetite, drowsiness and irritability. Fever was defined as an axillary temperature greater than or equal to (\>=) 37.5 degree Celsius (C), and categorized as \>=37.5 to 38.4 degree C, greater than (\>)38.4 to 38.9 degree C,\>38.9 to 40.0 degree C and \>40.0 degree C; decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed); drowsiness was graded as mild (increased or prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity); Irritability: graded as mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted).

    Time frame: Within 7 Days After Dose 1

  6. Percentage of Participants With Systemic Events Within 7 Days After Dose 2

    Systemic events included fever, decreased appetite, drowsiness and irritability. Fever was defined as an axillary temperature \>=37.5 degree C and categorized as \>=37.5 to 38.4 degree C,\>38.4 to 38.9 degree C,\>38.9 to 40.0 degree C and \>40.0 degree C; decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed); drowsiness was graded as mild (increased or prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity); Irritability: graded as mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted).

    Time frame: Within 7 Days After Dose 2

  7. Percentage of Participants With Systemic Events Within 7 Days After Dose 3

    Systemic events included fever, decreased appetite, drowsiness and irritability. Fever was defined as an axillary temperature \>=37.5 degree C and categorized as \>=37.5 to 38.4 degree C,\>38.4 to 38.9 degree C,\>38.9 to 40.0 degree C and \>40.0 degree C; decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed); drowsiness was graded as mild (increased or prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity); Irritability: graded as mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted).

    Time frame: Within 7 Days After Dose 3

  8. Percentage of Participants With Systemic Events Within 7 Days After Dose 4

    Systemic events included fever, decreased appetite, drowsiness and irritability. Fever was defined as an axillary temperature \>=37.5 degree C and categorized as \>=37.5 to 38.4 degree C,\>38.4 to 38.9 degree C,\>38.9 to 40.0 degree C and \>40.0 degree C; decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed); drowsiness was graded as mild (increased or prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity); Irritability: graded as mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted).

    Time frame: Within 7 Days After Dose 4

  9. Percentage of Participants With Adverse Events (AEs) From Dose 1 to 1 Month After Dose 3

    An adverse event (AE) was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment.

    Time frame: Day 1 of Dose 1 to 1 Month after Dose 3

  10. Percentage of Participants With AEs From Dose 4 to 1 Month After Dose 4

    An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment.

    Time frame: From Dose 4 to 1 Month after Dose 4

  11. Percentage of Participants With Serious Adverse Events (SAEs) From Dose 1 to 1 Month After Dose 4

    A serious AE was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent or significant disability/ incapacity; congenital anomaly/birth defect and other important medical events.

    Time frame: From Dose 1 to 1 Month after Dose 4

  12. Percentage of Participants With Newly Diagnosed Chronic Medical Conditions (NDCMCs) From Dose 1 to 1 Month After Dose 4

    An NDCMC was defined as a significant disease or medical condition, not previously identified, that is expected to be persistent or was otherwise long-lasting in its effects.

    Time frame: From Dose 1 to 1 Month after Dose 4

  13. Percentage of Participants With Predefined Pneumococcal Serotype-specific Immunoglobulin G (IgG) Concentrations 1 Month After Dose 3

    Pneumococcal serotype-specific IgG Concentrations were measured for 20vPnC serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F. Assay results below the lower limit of quantitation (LLOQ) were set to 0.5\*LLOQ. The predefined levels, \>=0.35 micrograms/mL for all serotypes except for serotypes 5 (\>=0.23 micrograms/mL), 6B (\>=0.10 micrograms/mL) and 19A (\>=0.12 micrograms/mL).

    Time frame: 1 Month after Dose 3

Secondary outcomes

  1. Geometric Mean Concentration of Pneumococcal Serotype-Specific IgG Concentrations 1 Month After Dose 3

    Pneumococcal serotype-specific IgG concentrations were measured for 20vPnC serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F. Assay results below the LLOQ were set to 0.5\*LLOQ.

    Time frame: 1 Month after Dose 3

  2. Geometric Mean Concentration of Pneumococcal Serotype-Specific IgG Concentrations 1 Month After Dose 4

    Pneumococcal serotype-specific IgG concentrations were measured for 20vPnC serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F.

    Time frame: 1 Month after Dose 4

  3. Geometric Mean Titer (GMTs) of Serotype Specific Opsonophagocytic Activity (OPA) at 1 Month After Dose 3, Before Dose 4 and 1 Month After Dose 4

    20vPnC serotypes included: 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F. OPA titers were determined in randomly selected subsets of sera from each vaccine group.

    Time frame: 1 Month after Dose 3, before Dose 4 and 1 Month after Dose 4

  4. Percentage of Participants With Pre-defined Pneumococcal Serotype-specific IgG Concentrations at 1 Month After Dose 4

    Pneumococcal serotype-specific IgG concentrations were measured for 20vPnC serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F. The predefined levels, \>=0.35 micrograms/mL for all serotypes except for serotypes 5 (\>=0.23 micrograms/mL), 6B (\>=0.10 micrograms/mL) and 19A (\>=0.12 micrograms/mL).

    Time frame: 1 Month after Dose 4

  5. Geometric Mean Fold Rise (GMFR) in Serotype-Specific IgG Concentrations From 1 Month After Dose 3 to Before Dose 4

    GMFR of pneumococcal 20vPnC serotypes included: 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F. The GMFR from 1 month after Dose 3 to before Dose 4 was reported from participants in Dose 3 evaluable immunogenicity population.

    Time frame: 1 Month after Dose 3 to before Dose 4

  6. GMFR in Serotype-Specific IgG Concentrations From 1 Month After Dose 3 to 1 Month After Dose 4

    GMFR of pneumococcal 20vPnC serotypes included: 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F. The GMFR from 1 month after Dose 3 to 1 month after Dose 4 was reported from participants in both the Dose 3 and Dose 4 evaluable immunogenicity population.

    Time frame: From 1 Month after Dose 3 to 1 Month after Dose 4

  7. GMFR in Serotype-Specific IgG Concentrations From Before Dose 4 to 1 Month After Dose 4

    GMFR of pneumococcal 20vPnC serotypes included: 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F. The GMFR from before Dose 4 to 1 month after Dose 4 was reported from participants in the Dose 4 evaluable immunogenicity population.

    Time frame: From before Dose 4 to 1 Month after Dose 4

07

Results

Posted Apr 21, 2023

Participant flow

Participant flow — Overall Study
Milestone20vPnC (SC)13vPnC (SC)20vPnC (IM)
Started225224217
Completed217220211
Not completed846
Withdrew: Other210
Withdrew: Physician decision001
Withdrew: Death001
Withdrew: Adverse event010
Withdrew: No longer meets eligibility criteria102
Withdrew: Withdrawal by parent/guardian522

Outcome measures

PrimaryPercentage of Participants With Local Reactions (LR) Within 7 Days After Dose 1

Local reactions included pain at injection site, redness and swelling were measured and recorded in measuring device (caliper) units. 1 measuring device unit =0.5 centimeter (cm). Pain at injection site was graded as mild: hurts if gently touched; moderate: hurts if gently touched with crying; severe: limited limb movement. Redness and swelling were graded as mild: \>0 to 2.0 cm; moderate \>2.0 to 7.0 cm; and severe: \>7.0 cm.

Time frame:
Within 7 Days after Dose 1
Reported as:
Number · Percentage of participants
Percentage of Participants With Local Reactions (LR) Within 7 Days After Dose 1
Percentage of participants20vPnC (SC)13vPnC (SC)20vPnC (IM)
Redness: Mild58.2 ± 51.551.3 ± 44.626.3 ± 20.5
Redness: Moderate20.0 ± 15.023.7 ± 18.311.1 ± 7.2
Redness: Severe0 ± 0.00 ± 0.00 ± 0.0
Swelling: Mild48.9 ± 42.242.9 ± 36.317.5 ± 12.7
Swelling: Moderate19.6 ± 14.623.2 ± 17.911.1 ± 7.2
Swelling: Severe0 ± 0.00 ± 0.00 ± 0.0
Pain at the injection site: Mild15.6 ± 11.113.4 ± 9.212.4 ± 8.4
Pain at the injection site: Moderate1.8 ± 0.52.7 ± 1.03.2 ± 1.3
Pain at the injection site: Severe0 ± 0.00 ± 0.00.5 ± 0.0
PrimaryPercentage of Participants With Local Reactions Within 7 Days After Dose 2

Local reactions included pain at injection site, redness and swelling were measured and recorded in measuring device (caliper) units. 1 measuring device unit =0.5 cm. Pain at injection site was graded as mild: hurts if gently touched; moderate: hurts if gently touched with crying; severe: limited limb movement. Redness and swelling were graded as mild: \>0 to 2.0 cm; moderate \>2.0 to 7.0 cm; and severe: \>7.0 cm.

Time frame:
Within 7 Days after Dose 2
Reported as:
Number · Percentage of participants
Percentage of Participants With Local Reactions Within 7 Days After Dose 2
Percentage of participants20vPnC (SC)13vPnC (SC)20vPnC (IM)
Redness: Mild52.9 ± 46.153.2 ± 46.424.7 ± 19.0
Redness: Moderate23.3 ± 17.931.1 ± 25.17.0 ± 4.0
Redness: Severe0 ± 0.00 ± 0.00 ± 0.0
Swelling: Mild46.2 ± 39.546.8 ± 40.118.1 ± 13.2
Swelling: Moderate22.4 ± 17.126.6 ± 20.97.9 ± 4.7
Swelling: Severe0 ± 0.00 ± 0.00 ± 0.0
Pain at the injection site: Mild13.0 ± 8.916.7 ± 12.09.3 ± 5.8
Pain at the injection site: Moderate3.6 ± 1.60.5 ± 0.02.3 ± 0.8
Pain at the injection site: Severe0 ± 0.00 ± 0.00 ± 0.0
PrimaryPercentage of Participants With Local Reactions Within 7 Days After Dose 3

Local reactions included pain at injection site, redness and swelling were measured and recorded in measuring device (caliper) units. 1 measuring device unit =0.5 cm. Pain at injection site was graded as mild: hurts if gently touched; moderate: hurts if gently touched with crying; severe: limited limb movement. Redness and swelling were graded as mild: \>0 to 2.0 cm; moderate \>2.0 to 7.0 cm; and severe: \>7.0 cm.

Time frame:
Within 7 Days after Dose 3
Reported as:
Number · Percentage of participants
Percentage of Participants With Local Reactions Within 7 Days After Dose 3
Percentage of participants20vPnC (SC)13vPnC (SC)20vPnC (IM)
Redness: Mild45.0 (38.4 to 51.8)51.1 (44.3 to 57.9)23.3 (17.8 to 29.5)
Redness: Moderate33.8 (27.6 to 40.4)34.8 (28.6 to 41.5)8.4 (5.0 to 12.9)
Redness: Severe0 (0.0 to 1.6)0 (0.0 to 1.7)0 (0.0 to 1.7)
Swelling: Mild38.7 (32.3 to 45.5)39.8 (33.3 to 46.6)17.7 (12.8 to 23.4)
Swelling: Moderate30.2 (24.2 to 36.7)35.3 (29.0 to 42.0)9.8 (6.1 to 14.5)
Swelling: Severe0 (0.0 to 1.6)0 (0.0 to 1.7)0 (0.0 to 1.7)
Pain at the injection site: Mild10.8 (7.1 to 15.7)14.5 (10.1 to 19.8)8.8 (5.4 to 13.5)
Pain at the injection site: Moderate3.6 (1.6 to 7.0)1.4 (0.3 to 3.9)0.9 (0.1 to 3.3)
Pain at the injection site: Severe0 (0.0 to 1.6)0 (0.0 to 1.7)0.5 (0.0 to 2.6)
PrimaryPercentage of Participants With Local Reactions Within 7 Days After Dose 4

Local reactions included pain at injection site, redness and swelling were measured and recorded in measuring device (caliper) units. 1 measuring device unit =0.5 cm. Pain at injection site was graded as mild: hurts if gently touched; moderate: hurts if gently touched with crying; severe: limited limb movement. Redness and swelling were graded as mild: \>0 to 2.0 cm; moderate \>2.0 to 7.0 cm; and severe: \>7.0 cm.

Time frame:
Within 7 Days after Dose 4
Reported as:
Number · Percentage of participants
Percentage of Participants With Local Reactions Within 7 Days After Dose 4
Percentage of participants20vPnC (SC)13vPnC (SC)20vPnC (IM)
Redness: Mild37.2 (30.7 to 43.9)36.4 (30.0 to 43.1)20.8 (15.5 to 26.8)
Redness: Moderate49.1 (42.3 to 55.9)49.1 (42.3 to 55.9)11.8 (7.8 to 16.9)
Redness: Severe0.5 (0.0 to 2.5)0.5 (0.0 to 2.5)0 (0.0 to 1.7)
Swelling: Mild37.6 (31.2 to 44.4)35.9 (29.6 to 42.6)13.2 (9.0 to 18.5)
Swelling: Moderate42.2 (35.6 to 49.1)41.8 (35.2 to 48.6)10.8 (7.0 to 15.8)
Swelling: Severe0.5 (0.0 to 2.5)0 (0.0 to 1.7)0 (0.0 to 1.7)
Pain at the injection site: Mild19.7 (14.7 to 25.6)19.1 (14.1 to 24.9)10.4 (6.6 to 15.3)
Pain at the injection site: Moderate1.4 (0.3 to 4.0)3.2 (1.3 to 6.4)3.3 (1.3 to 6.7)
Pain at the injection site: Severe0 (0.0 to 1.7)0 (0.0 to 1.7)0 (0.0 to 1.7)
PrimaryPercentage of Participants With Systemic Events Within 7 Days After Dose 1

Systemic events included fever, decreased appetite, drowsiness and irritability. Fever was defined as an axillary temperature greater than or equal to (\>=) 37.5 degree Celsius (C), and categorized as \>=37.5 to 38.4 degree C, greater than (\>)38.4 to 38.9 degree C,\>38.9 to 40.0 degree C and \>40.0 degree C; decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed); drowsiness was graded as mild (increased or prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity); Irritability: graded as mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted).

Time frame:
Within 7 Days After Dose 1
Reported as:
Number · Percentage of participants
Percentage of Participants With Systemic Events Within 7 Days After Dose 1
Percentage of participants20vPnC (SC)13vPnC (SC)20vPnC (IM)
Fever: >=37.5 degree C9.8 ± 6.212.9 ± 8.89.7 ± 6.1
Fever: >=37.5°C to 38.4 degree C9.3 ± 5.912.5 ± 8.59.7 ± 6.1
Fever: >38.4°C to 38.9 degree C0.4 ± 0.00.4 ± 0.00 ± 0.0
Fever: >38.9 to 40.0 degree C0 ± 0.00 ± 0.00 ± 0.0
Fever: >40.0 degree C0 ± 0.00 ± 0.00 ± 0.0
Decreased appetite: Mild3.6 ± 1.57.1 ± 4.13.2 ± 1.3
Decreased appetite: Moderate1.8 ± 0.53.1 ± 1.33.2 ± 1.3
Decreased appetite: Severe0 ± 0.00.4 ± 0.00 ± 0.0
Drowsiness: Mild40.4 ± 34.042.0 ± 35.442.9 ± 36.2
Drowsiness: Moderate0.9 ± 0.12.2 ± 0.74.1 ± 1.9
Drowsiness: Severe0 ± 0.00.4 ± 0.00 ± 0.0
Irritability: Mild13.8 ± 9.611.2 ± 7.412.9 ± 8.7
Irritability: Moderate12.0 ± 8.113.4 ± 9.211.5 ± 7.6
Irritability: Severe1.3 ± 0.31.8 ± 0.50.5 ± 0.0
PrimaryPercentage of Participants With Systemic Events Within 7 Days After Dose 2

Systemic events included fever, decreased appetite, drowsiness and irritability. Fever was defined as an axillary temperature \>=37.5 degree C and categorized as \>=37.5 to 38.4 degree C,\>38.4 to 38.9 degree C,\>38.9 to 40.0 degree C and \>40.0 degree C; decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed); drowsiness was graded as mild (increased or prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity); Irritability: graded as mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted).

Time frame:
Within 7 Days After Dose 2
Reported as:
Number · Percentage of participants
Percentage of Participants With Systemic Events Within 7 Days After Dose 2
Percentage of participants20vPnC (SC)13vPnC (SC)20vPnC (IM)
Fever: >=37.5 degree C20.2 ± 15.121.2 ± 16.018.1 ± 13.2
Fever: >=37.5 to 38.4 degree C15.2 ± 10.817.6 ± 12.814.9 ± 10.4
Fever: >38.4 to 38.9 degree C3.1 ± 1.32.3 ± 0.71.9 ± 0.5
Fever: >38.9 to 40.0 degree C1.8 ± 0.51.4 ± 0.31.4 ± 0.3
Fever: >40.0 degree C0 ± 0.00 ± 0.00 ± 0.0
Decreased appetite: Mild4.5 ± 2.26.8 ± 3.85.1 ± 2.6
Decreased appetite: Moderate5.8 ± 3.15.0 ± 2.54.7 ± 2.3
Decreased appetite: Severe0 ± 0.00 ± 0.00 ± 0.0
Drowsiness: Mild39.9 ± 33.448.6 ± 41.939.5 ± 33.0
Drowsiness: Moderate3.1 ± 1.34.1 ± 1.92.3 ± 0.8
Drowsiness: Severe0 ± 0.00 ± 0.00 ± 0.0
Irritability: Mild12.6 ± 8.516.7 ± 12.010.2 ± 6.5
Irritability: Moderate12.1 ± 8.114.9 ± 10.515.3 ± 10.8
Irritability: Severe1.3 ± 0.30.5 ± 0.01.4 ± 0.3
PrimaryPercentage of Participants With Systemic Events Within 7 Days After Dose 3

Systemic events included fever, decreased appetite, drowsiness and irritability. Fever was defined as an axillary temperature \>=37.5 degree C and categorized as \>=37.5 to 38.4 degree C,\>38.4 to 38.9 degree C,\>38.9 to 40.0 degree C and \>40.0 degree C; decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed); drowsiness was graded as mild (increased or prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity); Irritability: graded as mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted).

Time frame:
Within 7 Days After Dose 3
Reported as:
Number · Percentage of participants
Percentage of Participants With Systemic Events Within 7 Days After Dose 3
Percentage of participants20vPnC (SC)13vPnC (SC)20vPnC (IM)
Fever: >=37.5 degree C15.3 ± 10.819.9 ± 14.915.3 ± 10.8
Fever: >=37.5 to 38.4 degree C13.5 ± 9.316.3 ± 11.712.6 ± 8.4
Fever: >38.4 to 38.9 degree C1.4 ± 0.32.7 ± 1.01.9 ± 0.5
Fever: >38.9 to 40.0 degree C0.5 ± 0.00.9 ± 0.10.9 ± 0.1
Fever: >40.0 degree C0 ± 0.00 ± 0.00 ± 0.0
Decreased appetite: Mild5.0 ± 2.57.2 ± 4.24.2 ± 1.9
Decreased appetite: Moderate2.7 ± 1.03.6 ± 1.63.7 ± 1.6
Decreased appetite: Severe0.5 ± 0.00 ± 0.00 ± 0.0
Drowsiness: Mild24.8 ± 19.232.6 ± 26.432.6 ± 26.3
Drowsiness: Moderate1.4 ± 0.31.8 ± 0.51.4 ± 0.3
Drowsiness: Severe0 ± 0.00 ± 0.00 ± 0.0
Irritability: Mild16.7 ± 12.010.9 ± 7.114.0 ± 9.6
Irritability: Moderate8.6 ± 5.29.0 ± 5.613.0 ± 8.8
Irritability: Severe0.5 ± 0.00 ± 0.00.9 ± 0.1
PrimaryPercentage of Participants With Systemic Events Within 7 Days After Dose 4

Systemic events included fever, decreased appetite, drowsiness and irritability. Fever was defined as an axillary temperature \>=37.5 degree C and categorized as \>=37.5 to 38.4 degree C,\>38.4 to 38.9 degree C,\>38.9 to 40.0 degree C and \>40.0 degree C; decreased appetite was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed); drowsiness was graded as mild (increased or prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity); Irritability: graded as mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted).

Time frame:
Within 7 Days After Dose 4
Reported as:
Number · Percentage of participants
Percentage of Participants With Systemic Events Within 7 Days After Dose 4
Percentage of participants20vPnC (SC)13vPnC (SC)20vPnC (IM)
Fever: >=37.5 degree C42.7 ± 36.039.5 ± 33.038.2 ± 31.6
Fever: >=37.5 to 38.4 degree C25.7 ± 20.029.1 ± 23.224.1 ± 18.5
Fever: >38.4 to 38.9 degree C10.1 ± 6.45.9 ± 3.26.1 ± 3.3
Fever: >38.9 to 40.0 degree C6.4 ± 3.64.5 ± 2.28.0 ± 4.7
Fever: >40.0 degree C0.5 ± 0.00 ± 0.00 ± 0.0
Decreased appetite: Mild6.4 ± 3.66.8 ± 3.96.1 ± 3.3
Decreased appetite: Moderate7.3 ± 4.37.7 ± 4.65.7 ± 3.0
Decreased appetite: Severe0 ± 0.00 ± 0.00.9 ± 0.1
Drowsiness: Mild24.3 ± 18.823.6 ± 18.229.7 ± 23.7
Drowsiness: Moderate1.4 ± 0.32.3 ± 0.71.9 ± 0.5
Drowsiness: Severe0 ± 0.00 ± 0.00 ± 0.0
Irritability: Mild14.2 ± 9.915.5 ± 10.915.1 ± 10.6
Irritability: Moderate7.3 ± 4.311.4 ± 7.59.4 ± 5.9
Irritability: Severe0.9 ± 0.10.9 ± 0.10.5 ± 0.0
PrimaryPercentage of Participants With Adverse Events (AEs) From Dose 1 to 1 Month After Dose 3

An adverse event (AE) was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment.

Time frame:
Day 1 of Dose 1 to 1 Month after Dose 3
Reported as:
Number · Percentage of participants
Percentage of Participants With Adverse Events (AEs) From Dose 1 to 1 Month After Dose 3
Percentage of participants20vPnC (SC)13vPnC (SC)20vPnC (IM)
Percentage of Participants With Adverse Events (AEs) From Dose 1 to 1 Month After Dose 347.6 ± 40.955.4 ± 48.658.5 ± 51.7
PrimaryPercentage of Participants With AEs From Dose 4 to 1 Month After Dose 4

An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment.

Time frame:
From Dose 4 to 1 Month after Dose 4
Reported as:
Number · Percentage of participants
Percentage of Participants With AEs From Dose 4 to 1 Month After Dose 4
Percentage of participants20vPnC (SC)13vPnC (SC)20vPnC (IM)
Percentage of Participants With AEs From Dose 4 to 1 Month After Dose 440.4 ± 33.843.2 ± 36.543.9 ± 37.1
PrimaryPercentage of Participants With Serious Adverse Events (SAEs) From Dose 1 to 1 Month After Dose 4

A serious AE was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent or significant disability/ incapacity; congenital anomaly/birth defect and other important medical events.

Time frame:
From Dose 1 to 1 Month after Dose 4
Reported as:
Number · Percentage of participants
Percentage of Participants With Serious Adverse Events (SAEs) From Dose 1 to 1 Month After Dose 4
Percentage of participants20vPnC (SC)13vPnC (SC)20vPnC (IM)
Percentage of Participants With Serious Adverse Events (SAEs) From Dose 1 to 1 Month After Dose 46.2 ± 3.44.0 ± 1.97.4 ± 4.3
PrimaryPercentage of Participants With Newly Diagnosed Chronic Medical Conditions (NDCMCs) From Dose 1 to 1 Month After Dose 4

An NDCMC was defined as a significant disease or medical condition, not previously identified, that is expected to be persistent or was otherwise long-lasting in its effects.

Time frame:
From Dose 1 to 1 Month after Dose 4
Reported as:
Number · Percentage of participants
Percentage of Participants With Newly Diagnosed Chronic Medical Conditions (NDCMCs) From Dose 1 to 1 Month After Dose 4
Percentage of participants20vPnC (SC)13vPnC (SC)20vPnC (IM)
Percentage of Participants With Newly Diagnosed Chronic Medical Conditions (NDCMCs) From Dose 1 to 1 Month After Dose 410.7 ± 7.08.9 ± 5.58.3 ± 5.0
PrimaryPercentage of Participants With Predefined Pneumococcal Serotype-specific Immunoglobulin G (IgG) Concentrations 1 Month After Dose 3

Pneumococcal serotype-specific IgG Concentrations were measured for 20vPnC serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F. Assay results below the lower limit of quantitation (LLOQ) were set to 0.5\*LLOQ. The predefined levels, \>=0.35 micrograms/mL for all serotypes except for serotypes 5 (\>=0.23 micrograms/mL), 6B (\>=0.10 micrograms/mL) and 19A (\>=0.12 micrograms/mL).

Time frame:
1 Month after Dose 3
Reported as:
Number · Percentage of participants
Percentage of Participants With Predefined Pneumococcal Serotype-specific Immunoglobulin G (IgG) Concentrations 1 Month After Dose 3
Percentage of participants20vPnC (SC)13vPnC (SC)20vPnC (IM)
Serotype: 197.7 (94.8 to 99.3)99.1 (96.8 to 99.9)92.0 (87.5 to 95.3)
Serotype: 396.4 (93.0 to 98.4)99.1 (96.8 to 99.9)95.3 (91.5 to 97.7)
Serotype: 496.8 (93.6 to 98.7)99.1 (96.8 to 99.9)94.8 (90.9 to 97.4)
Serotype: 592.3 (88.0 to 95.5)97.3 (94.2 to 99.0)93.0 (88.7 to 96.0)
Serotype: 6A90.0 (85.3 to 93.7)98.2 (95.4 to 99.5)94.8 (90.9 to 97.4)
Serotype: 6B87.8 (82.7 to 91.8)96.4 (93.0 to 98.4)82.2 (76.3 to 87.1)
Serotype: 7F95.9 (92.4 to 98.1)99.1 (96.8 to 99.9)94.8 (90.9 to 97.4)
Serotype: 9V95.9 (92.4 to 98.1)98.6 (96.1 to 99.7)93.0 (88.7 to 96.0)
Serotype: 1496.8 (93.6 to 98.7)97.7 (94.8 to 99.3)96.2 (92.7 to 98.4)
Serotype: 18C96.8 (93.6 to 98.7)99.1 (96.8 to 99.9)94.8 (90.9 to 97.4)
Serotype: 19A99.5 (97.5 to 100.0)99.5 (97.5 to 100.0)99.1 (96.6 to 99.9)
Serotype: 19F100.0 (98.3 to 100.0)100.0 (98.3 to 100.0)100.0 (98.3 to 100.0)
Serotype: 23F89.6 (84.8 to 93.3)93.6 (89.6 to 96.5)88.7 (83.7 to 92.6)
Serotype: 899.5 (97.5 to 100.0)0.9 (0.1 to 3.3)99.5 (97.4 to 100.0)
Serotype: 10A60.2 (53.4 to 66.7)1.8 (0.5 to 4.6)59.6 (52.7 to 66.3)
Serotype: 11A100.0 (98.3 to 100.0)2.7 (1.0 to 5.8)100.0 (98.3 to 100.0)
Serotype: 12F74.7 (68.4 to 80.3)0.9 (0.1 to 3.2)74.6 (68.3 to 80.3)
Serotype: 15B99.1 (96.8 to 99.9)8.2 (4.9 to 12.6)98.6 (95.9 to 99.7)
Serotype: 22F100.0 (98.3 to 100.0)0.9 (0.1 to 3.2)100.0 (98.3 to 100.0)
Serotype: 33F95.0 (91.2 to 97.5)3.2 (1.3 to 6.4)92.5 (88.0 to 95.6)
Statistical analysis
  • 20vPnC (SC) vs 13vPnC (SC) · Percentage difference: -1.4 · 95% CI -4.4 to 1.3
  • 20vPnC (SC) vs 13vPnC (SC) · Percentage difference: -2.7 · 95% CI -6.2 to 0.1
  • 20vPnC (SC) vs 13vPnC (SC) · Percentage difference: -2.3 · 95% CI -5.6 to 0.5
  • 20vPnC (SC) vs 13vPnC (SC) · Percentage difference: -5.0 · 95% CI -9.6 to -0.9
  • 20vPnC (SC) vs 13vPnC (SC) · Percentage difference: -8.1 · 95% CI -13.0 to -4.0
  • 20vPnC (SC) vs 13vPnC (SC) · Percentage difference: -8.6 · 95% CI -14.0 to -3.7
  • 20vPnC (SC) vs 13vPnC (SC) · Percentage difference: -3.2 · 95% CI -6.8 to -0.3
  • 20vPnC (SC) vs 13vPnC (SC) · Percentage difference: -2.7 · 95% CI -6.4 to 0.4
  • 20vPnC (SC) vs 13vPnC (SC) · Percentage difference: -0.9 · 95% CI -4.4 to 2.4
  • 20vPnC (SC) vs 13vPnC (SC) · Percentage difference: -2.3 · 95% CI -5.6 to 0.5
  • 20vPnC (SC) vs 13vPnC (SC) · Percentage difference: 0.0 · 95% CI -2.1 to 2.1
  • 20vPnC (SC) vs 13vPnC (SC) · Percentage difference: 0.0 · 95% CI -1.7 to 1.7
  • 20vPnC (SC) vs 13vPnC (SC) · Percentage difference: -4.0 · 95% CI -9.5 to 1.2
  • 20vPnC (SC) vs 13vPnC (SC) · Percentage difference: 5.9 · 95% CI 3.0 to 10.0
  • 20vPnC (SC) vs 13vPnC (SC) · Percentage difference: -33.5 · 95% CI -40.7 to -26.2
  • 20vPnC (SC) vs 13vPnC (SC) · Percentage difference: 6.4 · 95% CI 3.8 to 10.4
  • 20vPnC (SC) vs 13vPnC (SC) · Percentage difference: -19.0 · 95% CI -25.7 to -12.5
  • 20vPnC (SC) vs 13vPnC (SC) · Percentage difference: 5.5 · 95% CI 2.2 to 9.6
  • 20vPnC (SC) vs 13vPnC (SC) · Percentage difference: 6.4 · 95% CI 3.8 to 10.4
  • 20vPnC (SC) vs 13vPnC (SC) · Percentage difference: 1.3 · 95% CI -3.2 to 6.0
  • 20vPnC (SC) vs 20vPnC (IM) · Percentage difference: -5.7 · 95% CI -10.4 to -1.7
  • 20vPnC (SC) vs 20vPnC (IM) · Percentage difference: -1.1 · 95% CI -5.2 to 2.9
  • 20vPnC (SC) vs 20vPnC (IM) · Percentage difference: -2.0 · 95% CI -6.2 to 1.9
  • 20vPnC (SC) vs 20vPnC (IM) · Percentage difference: 0.7 · 95% CI -4.5 to 5.8
  • 20vPnC (SC) vs 20vPnC (IM) · Percentage difference: 4.8 · 95% CI -0.2 to 10.0
  • 20vPnC (SC) vs 20vPnC (IM) · Percentage difference: -5.6 · 95% CI -12.5 to 1.1
  • 20vPnC (SC) vs 20vPnC (IM) · Percentage difference: -1.1 · 95% CI -5.4 to 3.1
  • 20vPnC (SC) vs 20vPnC (IM) · Percentage difference: -3.0 · 95% CI -7.7 to 1.4
  • 20vPnC (SC) vs 20vPnC (IM) · Percentage difference: -0.6 · 95% CI -4.4 to 3.2
  • 20vPnC (SC) vs 20vPnC (IM) · Percentage difference: -2.0 · 95% CI -6.2 to 1.9
  • 20vPnC (SC) vs 20vPnC (IM) · Percentage difference: -0.5 · 95% CI -3.0 to 1.7
  • 20vPnC (SC) vs 20vPnC (IM) · Percentage difference: 0.0 · 95% CI -1.8 to 1.7
  • 20vPnC (SC) vs 20vPnC (IM) · Percentage difference: -0.9 · 95% CI -6.9 to 5.1
  • 20vPnC (SC) vs 20vPnC (IM) · Percentage difference: 0.0 · 95% CI -2.2 to 2.1
  • 20vPnC (SC) vs 20vPnC (IM) · Percentage difference: -0.6 · 95% CI -9.8 to 8.6
  • 20vPnC (SC) vs 20vPnC (IM) · Percentage difference: 0.0 · 95% CI -1.8 to 1.7
  • 20vPnC (SC) vs 20vPnC (IM) · Percentage difference: 0.0 · 95% CI -8.2 to 8.2
  • 20vPnC (SC) vs 20vPnC (IM) · Percentage difference: -0.5 · 95% CI -3.3 to 2.0
  • 20vPnC (SC) vs 20vPnC (IM) · Percentage difference: 0.0 · 95% CI -1.8 to 1.7
  • 20vPnC (SC) vs 20vPnC (IM) · Percentage difference: -2.5 · 95% CI -7.5 to 2.2
SecondaryGeometric Mean Concentration of Pneumococcal Serotype-Specific IgG Concentrations 1 Month After Dose 3

Pneumococcal serotype-specific IgG concentrations were measured for 20vPnC serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F. Assay results below the LLOQ were set to 0.5\*LLOQ.

Time frame:
1 Month after Dose 3
Reported as:
Geometric mean · Micrograms per milliliter
Geometric Mean Concentration of Pneumococcal Serotype-Specific IgG Concentrations 1 Month After Dose 3
Micrograms per milliliter20vPnC (SC)13vPnC (SC)20vPnC (IM)
Serotype 11.37 (1.25 to 1.51)2.21 (1.98 to 2.47)1.17 (1.04 to 1.31)
Serotype 31.29 (1.18 to 1.41)1.81 (1.66 to 1.98)1.10 (0.99 to 1.22)
Serotype 41.76 (1.57 to 1.97)2.96 (2.64 to 3.32)1.73 (1.52 to 1.97)
Serotype 51.01 (0.89 to 1.16)1.72 (1.51 to 1.96)1.00 (0.87 to 1.14)
Serotype 6A1.38 (1.21 to 1.57)2.34 (2.09 to 2.62)1.64 (1.42 to 1.88)
Serotype 6B0.42 (0.35 to 0.50)0.83 (0.71 to 0.97)0.39 (0.32 to 0.48)
Serotype 7F1.58 (1.43 to 1.75)2.19 (1.95 to 2.46)1.52 (1.35 to 1.71)
Serotype 9V1.46 (1.32 to 1.61)2.11 (1.88 to 2.36)1.45 (1.29 to 1.64)
Serotype 142.79 (2.45 to 3.18)3.31 (2.90 to 3.78)2.43 (2.13 to 2.76)
Serotype 18C1.67 (1.51 to 1.86)2.52 (2.26 to 2.82)1.54 (1.38 to 1.72)
Serotype 19A2.41 (2.19 to 2.65)3.19 (2.86 to 3.56)2.36 (2.11 to 2.64)
Serotype 19F2.81 (2.60 to 3.04)3.73 (3.41 to 4.08)2.76 (2.53 to 3.02)
Serotype 23F1.32 (1.15 to 1.51)2.05 (1.79 to 2.34)1.29 (1.13 to 1.48)
Serotype 83.32 (3.05 to 3.61)0.01 (0.01 to 0.01)3.29 (2.97 to 3.64)
Serotype 10A0.50 (0.42 to 0.60)0.01 (0.01 to 0.02)0.47 (0.39 to 0.56)
Serotype 11A5.63 (5.17 to 6.14)0.02 (0.02 to 0.02)5.22 (4.73 to 5.77)
Serotype 12F0.79 (0.67 to 0.93)0.01 (0.01 to 0.01)0.72 (0.60 to 0.85)
Serotype 15B6.77 (6.04 to 7.60)0.04 (0.03 to 0.05)6.80 (6.03 to 7.67)
Serotype 22F4.94 (4.54 to 5.38)0.01 (0.00 to 0.01)4.41 (3.99 to 4.88)
Serotype 33F1.70 (1.51 to 1.92)0.02 (0.02 to 0.03)1.62 (1.40 to 1.87)
Statistical analysis
  • 20vPnC (SC) vs 13vPnC (SC) · Gmr: 0.62 · 95% CI 0.54 to 0.72
  • 20vPnC (SC) vs 13vPnC (SC) · Gmr: 0.71 · 95% CI 0.63 to 0.81
  • 20vPnC (SC) vs 13vPnC (SC) · Gmr: 0.60 · 95% CI 0.51 to 0.70
  • 20vPnC (SC) vs 13vPnC (SC) · Gmr: 0.59 · 95% CI 0.49 to 0.71
  • 20vPnC (SC) vs 13vPnC (SC) · Gmr: 0.59 · 95% CI 0.50 to 0.70
  • 20vPnC (SC) vs 13vPnC (SC) · Gmr: 0.51 · 95% CI 0.40 to 0.64
  • 20vPnC (SC) vs 13vPnC (SC) · Gmr: 0.72 · 95% CI 0.62 to 0.84
  • 20vPnC (SC) vs 13vPnC (SC) · Gmr: 0.69 · 95% CI 0.60 to 0.80
  • 20vPnC (SC) vs 13vPnC (SC) · Gmr: 0.84 · 95% CI 0.70 to 1.01
  • 20vPnC (SC) vs 13vPnC (SC) · Gmr: 0.66 · 95% CI 0.57 to 0.77
  • 20vPnC (SC) vs 13vPnC (SC) · Gmr: 0.76 · 95% CI 0.65 to 0.87
  • 20vPnC (SC) vs 13vPnC (SC) · Gmr: 0.75 · 95% CI 0.67 to 0.85
  • 20vPnC (SC) vs 13vPnC (SC) · Gmr: 0.64 · 95% CI 0.53 to 0.78
  • 20vPnC (SC) vs 13vPnC (SC) · Gmr: 4.01 · 95% CI 3.36 to 4.79
  • 20vPnC (SC) vs 13vPnC (SC) · Gmr: 0.60 · 95% CI 0.48 to 0.76
  • 20vPnC (SC) vs 13vPnC (SC) · Gmr: 6.80 · 95% CI 5.69 to 8.13
  • 20vPnC (SC) vs 13vPnC (SC) · Gmr: 0.95 · 95% CI 0.76 to 1.20
  • 20vPnC (SC) vs 13vPnC (SC) · Gmr: 8.18 · 95% CI 6.75 to 9.92
  • 20vPnC (SC) vs 13vPnC (SC) · Gmr: 5.97 · 95% CI 5.00 to 7.12
  • 20vPnC (SC) vs 13vPnC (SC) · Gmr: 2.06 · 95% CI 1.69 to 2.51
  • 20vPnC (SC) vs 20vPnC (IM) · Gmr: 0.85 · 95% CI 0.73 to 0.99
  • 20vPnC (SC) vs 20vPnC (IM) · Gmr: 0.85 · 95% CI 0.74 to 0.98
  • 20vPnC (SC) vs 20vPnC (IM) · Gmr: 0.98 · 95% CI 0.83 to 1.16
  • 20vPnC (SC) vs 20vPnC (IM) · Gmr: 0.98 · 95% CI 0.81 to 1.19
  • 20vPnC (SC) vs 20vPnC (IM) · Gmr: 1.19 · 95% CI 0.98 to 1.44
  • 20vPnC (SC) vs 20vPnC (IM) · Gmr: 0.93 · 95% CI 0.72 to 1.21
  • 20vPnC (SC) vs 20vPnC (IM) · Gmr: 0.96 · 95% CI 0.82 to 1.12
  • 20vPnC (SC) vs 20vPnC (IM) · Gmr: 0.99 · 95% CI 0.85 to 1.16
  • 20vPnC (SC) vs 20vPnC (IM) · Gmr: 0.87 · 95% CI 0.72 to 1.04
  • 20vPnC (SC) vs 20vPnC (IM) · Gmr: 0.92 · 95% CI 0.79 to 1.07
  • 20vPnC (SC) vs 20vPnC (IM) · Gmr: 0.98 · 95% CI 0.84 to 1.13
  • 20vPnC (SC) vs 20vPnC (IM) · Gmr: 0.98 · 95% CI 0.87 to 1.10
  • 20vPnC (SC) vs 20vPnC (IM) · Gmr: 0.98 · 95% CI 0.81 to 1.19
  • 20vPnC (SC) vs 20vPnC (IM) · Gmr: 0.99 · 95% CI 0.87 to 1.13
  • 20vPnC (SC) vs 20vPnC (IM) · Gmr: 0.94 · 95% CI 0.73 to 1.20
  • 20vPnC (SC) vs 20vPnC (IM) · Gmr: 0.93 · 95% CI 0.81 to 1.06
  • 20vPnC (SC) vs 20vPnC (IM) · Gmr: 0.91 · 95% CI 0.71 to 1.15
  • 20vPnC (SC) vs 20vPnC (IM) · Gmr: 1.00 · 95% CI 0.85 to 1.18
  • 20vPnC (SC) vs 20vPnC (IM) · Gmr: 0.89 · 95% CI 0.78 to 1.02
  • 20vPnC (SC) vs 20vPnC (IM) · Gmr: 0.95 · 95% CI 0.79 to 1.15
SecondaryGeometric Mean Concentration of Pneumococcal Serotype-Specific IgG Concentrations 1 Month After Dose 4

Pneumococcal serotype-specific IgG concentrations were measured for 20vPnC serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F.

Time frame:
1 Month after Dose 4
Reported as:
Geometric mean · Micrograms per milliliter
Geometric Mean Concentration of Pneumococcal Serotype-Specific IgG Concentrations 1 Month After Dose 4
Micrograms per milliliter20vPnC (SC)13vPnC (SC)20vPnC (IM)
Serotype 12.79 (2.50 to 3.12)4.62 (4.11 to 5.19)2.78 (2.47 to 3.12)
Serotype 30.97 (0.87 to 1.08)1.44 (1.30 to 1.59)1.08 (0.96 to 1.21)
Serotype 46.93 (6.14 to 7.83)10.01 (8.89 to 11.27)7.31 (6.51 to 8.20)
Serotype 52.96 (2.63 to 3.34)4.64 (4.13 to 5.21)2.94 (2.59 to 3.33)
Serotype 6A11.90 (10.61 to 13.34)17.25 (15.66 to 18.99)13.92 (12.43 to 15.59)
Serotype 6B7.18 (6.30 to 8.18)10.48 (9.46 to 11.61)7.50 (6.58 to 8.55)
Serotype 7F4.46 (4.04 to 4.92)6.62 (5.95 to 7.38)4.85 (4.34 to 5.42)
Serotype 9V4.54 (4.04 to 5.09)6.62 (5.93 to 7.39)5.38 (4.81 to 6.02)
Serotype 148.23 (7.27 to 9.31)10.30 (9.25 to 11.47)9.19 (8.10 to 10.43)
Serotype 18C3.95 (3.50 to 4.45)5.97 (5.27 to 6.75)3.81 (3.38 to 4.30)
Serotype 19A7.62 (6.82 to 8.52)8.97 (8.08 to 9.95)7.92 (7.06 to 8.89)
Serotype 19F8.74 (7.84 to 9.73)11.02 (9.96 to 12.20)8.56 (7.66 to 9.56)
Serotype 23F7.01 (6.16 to 7.97)11.76 (10.42 to 13.28)7.39 (6.49 to 8.42)
Serotype 85.84 (5.23 to 6.53)0.02 (0.02 to 0.03)5.88 (5.23 to 6.62)
Serotype 10A6.98 (6.13 to 7.93)0.01 (0.01 to 0.01)8.02 (7.02 to 9.16)
Serotype 11A5.73 (5.08 to 6.46)0.02 (0.01 to 0.02)5.78 (5.14 to 6.50)
Serotype 12F2.73 (2.41 to 3.09)0.01 (0.01 to 0.01)2.69 (2.36 to 3.06)
Serotype 15B18.45 (16.73 to 20.36)0.03 (0.03 to 0.04)21.83 (19.53 to 24.41)
Serotype 22F14.07 (12.67 to 15.63)0.00 (0.00 to 0.01)14.21 (12.61 to 16.00)
Serotype 33F10.29 (9.28 to 11.40)0.02 (0.01 to 0.02)11.13 (9.99 to 12.39)
SecondaryGeometric Mean Titer (GMTs) of Serotype Specific Opsonophagocytic Activity (OPA) at 1 Month After Dose 3, Before Dose 4 and 1 Month After Dose 4

20vPnC serotypes included: 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F. OPA titers were determined in randomly selected subsets of sera from each vaccine group.

Time frame:
1 Month after Dose 3, before Dose 4 and 1 Month after Dose 4
Reported as:
Geometric mean · Titers
Geometric Mean Titer (GMTs) of Serotype Specific Opsonophagocytic Activity (OPA) at 1 Month After Dose 3, Before Dose 4 and 1 Month After Dose 4
Titers20vPnC (SC)13vPnC (SC)20vPnC (IM)
Serotype 1:1 Month after Dose 355 (43 to 71)126 (104 to 152)56 (45 to 70)
Serotype 1:Before Dose. 411 (10 to 12)13 (11 to 16)10 (9 to 11)
Serotype 1:1 Month after Dose 4162 (125 to 210)386 (306 to 486)194 (150 to 251)
Serotype 3:1 Month after Dose 3107 (86 to 134)170 (147 to 196)120 (103 to 139)
Serotype 3:Before Dose 416 (13 to 20)20 (16 to 25)16 (12 to 20)
Serotype 3: 1 Month after Dose 4131 (114 to 150)193 (165 to 226)150 (126 to 179)
Serotype 4:1 Month after Dose 31864 (1565 to 2219)1768 (1393 to 2245)1617 (1298 to 2015)
Serotype 4: Before Dose 425 (18 to 37)44 (29 to 66)21 (15 to 28)
Serotype 4:1 Month after Dose 41627 (1232 to 2148)2038 (1471 to 2825)1544 (1224 to 1948)
Serotype 5:1 Month after Dose 395 (79 to 114)154 (131 to 183)91 (77 to 109)
Serotype 5:Before Dose 416 (15 to 17)18 (16 to 19)15 (14 to 16)
Serotype 5:1 Month after Dose 4172 (140 to 212)248 (204 to 303)141 (112 to 179)
Serotype 6A:1 Month after Dose 32709 (2283 to 3213)3339 (2777 to 4013)3120 (2562 to 3799)
Serotype 6A:Before Dose 483 (56 to 122)173 (116 to 258)95 (62 to 147)
Serotype 6A:1 Month after Dose 43249 (2686 to 3928)5455 (4379 to 6795)3489 (2831 to 4300)
Serotype 6B:1 Month after Dose 31548 (1247 to 1921)2489 (2005 to 3088)1563 (1215 to 2010)
Serotype 6B:Before Dose 440 (29 to 54)75 (49 to 115)44 (31 to 63)
Serotype 6B:1 Month after Dose 42304 (1811 to 2933)4319 (3478 to 5362)2552 (2006 to 3247)
Serotype 7F:1 Month after Dose 34160 (3406 to 5081)4428 (3821 to 5131)4491 (3675 to 5490)
Serotype 7F:Before Dose 4626 (436 to 899)761 (579 to 1000)689 (487 to 975)
Serotype 7F:1 Month after Dose 44735 (3824 to 5863)6361 (5024 to 8054)4703 (3704 to 5972)
Serotype 9V:1 Month after Dose 31807 (1432 to 2279)2388 (1986 to 2870)1929 (1554 to 2394)
Serotype 9V:Before Dose 4183 (134 to 251)204 (151 to 274)212 (149 to 302)
Serotype 9V:1 Month after Dose 44199 (3322 to 5309)5162 (4349 to 6127)4201 (3418 to 5164)
Serotype 14:1 Month after Dose 31922 (1429 to 2585)2593 (1999 to 3362)2103 (1527 to 2897)
Serotype 14:Before Dose 4426 (307 to 592)469 (346 to 634)357 (251 to 509)
Serotype 14:1 Month after Dose 41673 (1331 to 2102)1706 (1385 to 2102)2005 (1631 to 2463)
Serotype 18C:1 Month after Dose 35124 (4381 to 5992)5355 (4617 to 6212)4908 (4037 to 5967)
Serotype 18C:Before Dose 4122 (76 to 198)173 (112 to 267)89 (56 to 143)
Serotype 18C:1 Month after Dose 44477 (3528 to 5681)6315 (5081 to 7848)4249 (3355 to 5381)
Serotype 19A:1 Month after Dose 3638 (535 to 762)676 (551 to 830)553 (441 to 693)
Serotype 19A:Before Dose 413 (10 to 18)20 (14 to 28)12 (10 to 16)
Serotype 19A:1 Month after Dose 41860 (1530 to 2261)2534 (2044 to 3143)1722 (1379 to 2151)
Serotype 19F:1 Month after Dose 3449 (356 to 566)624 (494 to 788)488 (411 to 580)
Serotype 19F:Before Dose 426 (24 to 29)25 (24 to 26)26 (23 to 29)
Serotype 19F:1 Month after Dose 41071 (846 to 1356)1783 (1364 to 2331)962 (753 to 1230)
Serotype 23F:1 Month after Dose 31580 (1211 to 2061)1849 (1499 to 2281)1402 (1103 to 1782)
Serotype 23F:Before Dose 442 (24 to 73)62 (36 to 107)24 (15 to 39)
Serotype 23F:1 Month after Dose 42609 (2015 to 3377)3772 (2966 to 4796)2052 (1668 to 2523)
Serotype 8:1 Month after Dose 31532 (1215 to 1933)16 (15 to 18)1541 (1220 to 1946)
Serotype 8:Before Dose 4166 (119 to 230)20 (17 to 24)147 (105 to 205)
Serotype 8:1 Month after Dose 42970 (2412 to 3658)27 (20 to 36)3208 (2525 to 4077)
Serotype 10A:1 Month after Dose 36977 (5204 to 9354)40 (33 to 47)6780 (5436 to 8456)
Serotype 10A:Before Dose 41985 (1422 to 2772)78 (51 to 118)2066 (1439 to 2967)
Serotype 10A:1 Month after Dose 49030 (6855 to 11893)87 (56 to 136)8269 (6252 to 10937)
Serotype 11A:1 Month after Dose 31894 (1540 to 2330)58 (47 to 71)1838 (1451 to 2327)
Serotype 11A:Before Dose 4416 (258 to 670)95 (64 to 142)247 (150 to 405)
Serotype 11A: 1 Month after Dose 43958 (2973 to 5269)90 (62 to 132)4200 (3187 to 5534)
Serotype 12F:1 Month after Dose 335278 (23575 to 52790)24 (24 to 25)21475 (14378 to 32074)
Serotype 12F:Before Dose 43984 (3017 to 5261)35 (26 to 47)4904 (3909 to 6153)
Serotype 12F:1 Month after Dose 415611 (11336 to 21499)43 (31 to 60)18899 (14215 to 25125)
Serotype 15B:1 Month after Dose 36981 (5726 to 8511)17 (15 to 20)5707 (4129 to 7889)
Serotype 15B:Before Dose 4578 (345 to 969)26 (18 to 39)609 (331 to 1121)
Serotype 15B:1 Month after Dose 47280 (5594 to 9475)32 (20 to 50)7770 (6448 to 9363)
Serotype 22F:1 Month after Dose 321864 (16413 to 29125)10 (8 to 11)19276 (14969 to 24822)
Serotype 22F:Before Dose 42562 (1869 to 3512)16 (11 to 24)2014 (1477 to 2745)
Serotype 22F:1 Month after Dose 428435 (19414 to 41649)18 (12 to 27)23480 (17229 to 31998)
Serotype 33F:1 Month after Dose 320162 (13581 to 29930)177 (160 to 195)15931 (11550 to 21974)
Serotype 33F:Before Dose 45678 (4403 to 7321)539 (391 to 742)6835 (5080 to 9198)
Serotype 33F:1 Month after Dose 418997 (13140 to 27463)658 (480 to 904)26963 (18722 to 38830)
SecondaryPercentage of Participants With Pre-defined Pneumococcal Serotype-specific IgG Concentrations at 1 Month After Dose 4

Pneumococcal serotype-specific IgG concentrations were measured for 20vPnC serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F. The predefined levels, \>=0.35 micrograms/mL for all serotypes except for serotypes 5 (\>=0.23 micrograms/mL), 6B (\>=0.10 micrograms/mL) and 19A (\>=0.12 micrograms/mL).

Time frame:
1 Month after Dose 4
Reported as:
Number · Percentage of participants
Percentage of Participants With Pre-defined Pneumococcal Serotype-specific IgG Concentrations at 1 Month After Dose 4
Percentage of participants20vPnC (SC)13vPnC (SC)20vPnC (IM)
Serotype 199.1100.098.6
Serotype 391.798.691.5
Serotype 4100.0100.0100.0
Serotype 599.5100.099.5
Serotype 6A100.0100.0100.0
Serotype 6B100.0100.0100.0
Serotype 7F99.5100.0100.0
Serotype 9V99.5100.0100.0
Serotype 1499.199.5100.0
Serotype 18C99.5100.0100.0
Serotype 19A100.0100.0100.0
Serotype 19F100.0100.0100.0
Serotype 23F99.5100.099.5
Serotype 8100.03.2100.0
Serotype 10A99.10.999.5
Serotype 11A100.05.9100.0
Serotype 12F98.20.098.6
Serotype 15B100.08.6100.0
Serotype 22F100.01.8100.0
Serotype 33F100.02.7100.0
SecondaryGeometric Mean Fold Rise (GMFR) in Serotype-Specific IgG Concentrations From 1 Month After Dose 3 to Before Dose 4

GMFR of pneumococcal 20vPnC serotypes included: 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F. The GMFR from 1 month after Dose 3 to before Dose 4 was reported from participants in Dose 3 evaluable immunogenicity population.

Time frame:
1 Month after Dose 3 to before Dose 4
Reported as:
Geometric mean · Fold rise
Geometric Mean Fold Rise (GMFR) in Serotype-Specific IgG Concentrations From 1 Month After Dose 3 to Before Dose 4
Fold rise20vPnC (SC)13vPnC (SC)20vPnC (IM)
Serotype 10.2 (0.2 to 0.2)0.2 (0.2 to 0.2)0.2 (0.2 to 0.2)
Serotype 30.1 (0.1 to 0.1)0.1 (0.1 to 0.1)0.1 (0.1 to 0.1)
Serotype 40.3 (0.2 to 0.3)0.2 (0.2 to 0.3)0.3 (0.2 to 0.3)
Serotype 50.3 (0.2 to 0.3)0.2 (0.2 to 0.3)0.2 (0.2 to 0.3)
Serotype 6A0.5 (0.4 to 0.6)0.4 (0.4 to 0.4)0.4 (0.3 to 0.4)
Serotype 6B0.8 (0.6 to 0.9)0.5 (0.4 to 0.6)0.7 (0.6 to 0.8)
Serotype 7F0.5 (0.4 to 0.5)0.4 (0.4 to 0.5)0.5 (0.4 to 0.5)
Serotype 9V0.3 (0.2 to 0.3)0.3 (0.2 to 0.3)0.3 (0.2 to 0.3)
Serotype 140.7 (0.6 to 0.8)0.7 (0.6 to 0.8)0.7 (0.6 to 0.8)
Serotype 18C0.2 (0.2 to 0.2)0.2 (0.2 to 0.2)0.2 (0.2 to 0.2)
Serotype 19A0.1 (0.1 to 0.1)0.1 (0.1 to 0.1)0.1 (0.1 to 0.1)
Serotype 19F0.2 (0.1 to 0.2)0.1 (0.1 to 0.2)0.2 (0.1 to 0.2)
Serotype 23F0.2 (0.2 to 0.3)0.3 (0.2 to 0.3)0.3 (0.2 to 0.3)
Serotype 80.2 (0.1 to 0.2)1.4 (1.2 to 1.6)0.2 (0.1 to 0.2)
Serotype 10A2.2 (1.9 to 2.6)0.8 (0.6 to 0.9)2.3 (1.9 to 2.7)
Serotype 11A0.1 (0.1 to 0.2)0.8 (0.6 to 0.9)0.1 (0.1 to 0.2)
Serotype 12F0.4 (0.3 to 0.5)1.0 (0.9 to 1.1)0.4 (0.3 to 0.4)
Serotype 15B0.4 (0.4 to 0.5)0.6 (0.5 to 0.7)0.4 (0.3 to 0.4)
Serotype 22F0.4 (0.3 to 0.4)0.6 (0.5 to 0.8)0.4 (0.3 to 0.4)
Serotype 33F1.1 (0.9 to 1.2)0.6 (0.5 to 0.7)1.0 (0.9 to 1.2)
SecondaryGMFR in Serotype-Specific IgG Concentrations From 1 Month After Dose 3 to 1 Month After Dose 4

GMFR of pneumococcal 20vPnC serotypes included: 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F. The GMFR from 1 month after Dose 3 to 1 month after Dose 4 was reported from participants in both the Dose 3 and Dose 4 evaluable immunogenicity population.

Time frame:
From 1 Month after Dose 3 to 1 Month after Dose 4
Reported as:
Geometric mean · Fold rise
GMFR in Serotype-Specific IgG Concentrations From 1 Month After Dose 3 to 1 Month After Dose 4
Fold rise20vPnC (SC)13vPnC (SC)20vPnC (IM)
Serotype 12.0 (1.8 to 2.2)2.1 (1.9 to 2.3)2.4 (2.2 to 2.7)
Serotype 30.7 (0.7 to 0.8)0.8 (0.7 to 0.9)1.0 (0.9 to 1.1)
Serotype 43.9 (3.4 to 4.4)3.4 (3.0 to 3.8)4.3 (3.7 to 4.8)
Serotype 52.9 (2.6 to 3.3)2.7 (2.4 to 3.0)3.0 (2.6 to 3.4)
Serotype 6A8.6 (7.5 to 9.8)7.3 (6.5 to 8.3)8.6 (7.6 to 9.8)
Serotype 6B17.1 (14.3 to 20.4)12.6 (10.8 to 14.7)19.5 (16.2 to 23.5)
Serotype 7F2.8 (2.6 to 3.1)3.0 (2.7 to 3.3)3.3 (2.9 to 3.6)
Serotype 9V3.1 (2.8 to 3.5)3.1 (2.8 to 3.5)3.8 (3.4 to 4.2)
Serotype 142.9 (2.6 to 3.4)3.1 (2.7 to 3.6)3.9 (3.3 to 4.5)
Serotype 18C2.3 (2.1 to 2.6)2.4 (2.1 to 2.6)2.5 (2.3 to 2.8)
Serotype 19A3.2 (2.8 to 3.6)2.8 (2.5 to 3.1)3.4 (3.0 to 3.8)
Serotype 19F3.1 (2.8 to 3.4)2.9 (2.6 to 3.3)3.1 (2.8 to 3.5)
Serotype 23F5.3 (4.6 to 6.1)5.7 (5.0 to 6.5)5.8 (5.1 to 6.6)
Serotype 81.8 (1.6 to 2.0)1.7 (1.5 to 2.0)1.8 (1.6 to 2.0)
Serotype 10A14.0 (11.8 to 16.5)0.8 (0.7 to 1.0)17.5 (14.7 to 20.7)
Serotype 11A1.0 (0.9 to 1.1)0.8 (0.7 to 1.0)1.1 (1.0 to 1.2)
Serotype 12F3.4 (3.0 to 3.9)1.0 (1.0 to 1.1)3.9 (3.4 to 4.4)
Serotype 15B2.7 (2.4 to 3.1)0.9 (0.7 to 1.1)3.3 (2.9 to 3.7)
Serotype 22F2.9 (2.6 to 3.1)0.7 (0.6 to 0.9)3.2 (2.9 to 3.6)
Serotype 33F6.0 (5.3 to 6.7)0.7 (0.6 to 0.9)7.1 (6.2 to 8.1)
SecondaryGMFR in Serotype-Specific IgG Concentrations From Before Dose 4 to 1 Month After Dose 4

GMFR of pneumococcal 20vPnC serotypes included: 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F. The GMFR from before Dose 4 to 1 month after Dose 4 was reported from participants in the Dose 4 evaluable immunogenicity population.

Time frame:
From before Dose 4 to 1 Month after Dose 4
Reported as:
Geometric mean · Fold rise
GMFR in Serotype-Specific IgG Concentrations From Before Dose 4 to 1 Month After Dose 4
Fold rise20vPnC (SC)13vPnC (SC)20vPnC (IM)
Serotype 110.7 (9.6 to 11.9)12.1 (11.0 to 13.3)12.6 (11.3 to 14.0)
Serotype 37.5 (6.6 to 8.4)7.9 (7.1 to 8.8)8.9 (8.0 to 10.0)
Serotype 415.0 (13.2 to 17.1)14.3 (12.7 to 16.0)16.5 (14.8 to 18.5)
Serotype 510.8 (9.8 to 12.0)11.8 (10.7 to 13.1)12.2 (11.0 to 13.6)
Serotype 6A17.6 (15.7 to 19.6)18.4 (16.6 to 20.5)22.1 (19.8 to 24.7)
Serotype 6B22.3 (19.9 to 24.9)24.3 (21.9 to 27.0)26.9 (23.9 to 30.2)
Serotype 7F6.0 (5.5 to 6.6)7.2 (6.5 to 8.0)6.8 (6.2 to 7.5)
Serotype 9V11.8 (10.5 to 13.2)12.0 (10.8 to 13.3)13.9 (12.4 to 15.6)
Serotype 144.3 (3.8 to 4.9)4.4 (3.9 to 5.0)5.7 (5.0 to 6.6)
Serotype 18C11.7 (10.5 to 12.9)14.0 (12.7 to 15.4)12.7 (11.5 to 14.1)
Serotype 19A34.2 (30.0 to 38.9)37.6 (33.2 to 42.6)38.3 (33.4 to 44.0)
Serotype 19F18.8 (16.6 to 21.4)21.4 (19.0 to 24.2)19.9 (17.6 to 22.4)
Serotype 23F22.6 (20.1 to 25.5)22.6 (19.8 to 25.7)22.7 (20.1 to 25.7)
Serotype 810.8 (9.6 to 12.1)1.3 (1.2 to 1.4)11.2 (9.9 to 12.7)
Serotype 10A6.3 (5.6 to 7.1)1.1 (1.0 to 1.1)7.4 (6.6 to 8.3)
Serotype 11A7.0 (6.2 to 7.9)1.1 (1.0 to 1.2)8.1 (7.2 to 9.1)
Serotype 12F8.5 (7.6 to 9.4)1.0 (1.0 to 1.1)9.9 (8.9 to 10.9)
Serotype 15B6.8 (6.0 to 7.7)1.5 (1.3 to 1.6)8.7 (7.6 to 10.0)
Serotype 22F7.9 (7.1 to 8.8)1.2 (1.1 to 1.3)8.9 (8.1 to 9.9)
Serotype 33F5.7 (5.1 to 6.3)1.2 (1.1 to 1.3)6.9 (6.2 to 7.8)

Adverse events

Collected over LR and SE [systematic assessment (SA)] within 7 days after Dose 1, 2, 3, or 4; SAEs (non-SA): from Day 1 up to 1 month after Dose 4; other AEs (non-SA): from Dose 1 up to 1 month after Dose 3 and from Dose 4 up to 1 month after Dose 4. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
20vPnC (SC)0/225 (0%)14/225 (6.2%)222/225 (98.7%)
13vPnC (SC)0/224 (0%)9/224 (4%)223/224 (99.6%)
20vPnC (IM)1/217 (0.5%)16/217 (7.4%)211/217 (97.2%)
Most frequent serious events
Showing 10 of 29
Most frequent serious events
Event20vPnC (SC)13vPnC (SC)20vPnC (IM)
Respiratory syncytial virus bronchiolitisInfections and infestations4/2252/2241/217
Respiratory syncytial virus infectionInfections and infestations4/2251/2241/217
PyrexiaGeneral disorders1/2250/2242/217
Urinary tract infectionInfections and infestations0/2250/2242/217
Febrile convulsionNervous system disorders2/2250/2240/217
Cardio-respiratory arrestCardiac disorders0/2250/2241/217
LaryngomalaciaCongenital, familial and genetic disorders0/2250/2241/217
Food allergyImmune system disorders0/2250/2241/217
Asymptomatic COVID-19Infections and infestations0/2250/2241/217
Cellulitis orbitalInfections and infestations0/2250/2241/217
Most frequent other events
Showing 10 of 13
Most frequent other events
Event20vPnC (SC)13vPnC (SC)20vPnC (IM)
Injection site erythema (REDNESS)General disorders217/225217/224130/217
Injection site swelling (SWELLING)General disorders206/225211/224119/217
Hypersomnia (INCREASED SLEEP)Nervous system disorders147/225161/224154/217
Pyrexia (FEVER)General disorders136/225135/224110/217
Irritability (IRRITABILITY)Psychiatric disorders110/225119/224107/217
Injection site pain (PAIN)General disorders84/22585/22465/217
NasopharyngitisInfections and infestations49/22564/22466/217
Decreased appetite (DECREASED APPETITE)Metabolism and nutrition disorders62/22568/22455/217
EczemaSkin and subcutaneous tissue disorders22/22519/22432/217
Upper respiratory tract inflammationRespiratory, thoracic and mediastinal disorders18/22511/22415/217

Baseline characteristics

Safety population included all the participants who received at least 1 dose of the investigational product (IP) with safety follow up after any vaccination.

Age, Continuous
Age, Continuous(Months)20vPnC (SC)13vPnC (SC)20vPnC (IM)Total
Mean2.4 ± 0.332.4 ± 0.402.4 ± 0.422.4 ± 0.39
Sex: Female, Male
Sex: Female, Male(Participants)20vPnC (SC)13vPnC (SC)20vPnC (IM)Total
Female117114106337
Male108110111329
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)20vPnC (SC)13vPnC (SC)20vPnC (IM)Total
Hispanic or Latino0000
Not Hispanic or Latino225224217666
Unknown or Not Reported0000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)20vPnC (SC)13vPnC (SC)20vPnC (IM)Total
American Indian or Alaska Native0000
Asian225224217666
Native Hawaiian or Other Pacific Islander0000
Black or African American0000
White0000
More than one race0000
Unknown or Not Reported0000
08

Study locations

38 sites
  • NHO Nagoya Medical Center
    Nagoya-shi, Aichi 460-0001, Japan
  • TOYOTA Memorial Hospital
    Toyota-shi, Aichi 471-8513, Japan
  • Tsubaki Children's Clinic
    Chiba-shi, Chiba 260-0001, Japan
  • Sunrise Children's Clinic
    Funabashi-city, Chiba 273-0035, Japan
  • medical corporation Shigyo-no-kai Sotobo Children's Clinic
    Isumi-city, Chiba 299-4503, Japan
  • Sou Clinic
    Yotsukaido-shi, Chiba 284-0001, Japan
  • NHO Shimoshizu National Hospital
    Yotsukaido-shi, Chiba 284-0003, Japan
  • Fukui Aiiku Hospital
    Fukui-shi, Fukui 910-0833, Japan
  • Fukazawa Clinic
    Fukuoka-City, Fukuoka 813-0036, Japan
  • Shindo children's clinic
    Fukuoka-city, Fukuoka 814-0121, Japan
  • Inamitsu Children's Clinic
    Fukuoka-city, Fukuoka 819-0041, Japan
  • Shimomura Pediatrics Clinic
    Fukuoka-shi, Fukuoka 819-0002, Japan
  • Iizuka Hospital
    Iizuka, Fukuoka 820-8505, Japan
  • Yokoyama Children'S Clinic
    Kasuga-city, Fukuoka 816-0801, Japan
  • Yajima Children's Clinic
    Gifu-city, Gifu 500-8212, Japan
  • Azuma kodomo katei clinic
    Ebetsu Shi, Hokkaido 069-0816, Japan
  • Nishi Sapporo Pediatrics
    Sapporo shi, Hokkaido 0630061, Japan
  • Nakata pediatric clinic
    Sapporo, Hokkaido 003-0023, Japan
  • Yoshimura Child Clinic
    Akashi-City, Hyōgo 674-0068, Japan
  • Morino Kodomo Clinic
    Kawasaki-shi, Kanagawa 211-0063, Japan
  • MIURA Children's Clinic
    Kumamoto Shi, Kumamoto 862-0960, Japan
  • Sakuranbo Kodomo Clinic
    Kumamoto-shi, Kumamoto 862-0924, Japan
  • Matsuda Pediatric Clinic
    Kuwana-city, MIE 511-0865, Japan
  • Arakawa Family Clinic
    Nagano-shi, Nagano 381-0025, Japan
  • NHO Osaka Minami Medical Center
    Kawachinagano, Osaka 586-8521, Japan
  • Aizenbashi Hospital
    Osaka-City, Osaka 556-0005, Japan
  • NHO Ureshino Medical center
    Ureshino-shi, Saga 843-0393, Japan
  • Hanyu General Hospital
    Hanyu-shi, Saitama 348-0045, Japan
  • Enomoto Clinic
    Kumagaya-shi, Saitama 360-0018, Japan
  • Saiseikai Shiga Hospital
    Ritto-Shi, Shiga 520-3046, Japan
  • Sakiyama Pediatric Clinic
    Fuchu-city, Tokyo 183-0042, Japan
  • Saitoh-Clinic
    Nishitokyo-shi, Tokyo 202-0004, Japan
  • Inami Pediatrics
    Setagaya-ku, Tokyo 154-0002, Japan
  • Sasamoto Children's Clinic
    Setagaya-ku, Tokyo 157-0066, Japan
  • Futaba Clinic
    Shinjuku-ku, Tokyo 160-0017, Japan
  • Tamura Clinic
    Suginami-ku, Tokyo 167-0052, Japan
  • Childrens clinic of Kose
    Kofu-city, Yamanashi 400-0853, Japan
  • Takei Clinic
    Tsuru-shi, Yamanashi 402-0025, Japan
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2020 to primary completion in Apr 2022, 18 months.

Results were first posted in Apr 2023, 1 year after primary completion.

Of 81 industry-sponsored phase 3 interventional studies under Pneumococcal Infections, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 23. This study's 18 months is above that.

Counting every sponsor, half of 82 studies reached it within 13 months; a quarter within 9 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 25, 2020
First posted
Aug 28, 2020
StartActual
Sep 16, 2020
Primary completionActual
Apr 2, 2022
CompletionActual
Apr 2, 2022
Results first posted
Apr 21, 2023
Last update
Apr 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04530838
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Aug 28, 2020
Start date
Sep 16, 2020
Primary completion
Apr 2, 2022
Completion
Apr 2, 2022
Results posted
Apr 21, 2023
Last update
Apr 21, 2023

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pneumococcal 20-Valent Conjugate Vaccine

Start the discussion